rh-bFGF联合伤口护理软膏治疗慢性难愈性创面的临床研究OA
The Clinical Effect of rh-bFGF Combined with Ointment Wound Dressing in the Treatment of Chronic Refractory Wounds
目的:探究重组人碱性成纤维细胞生长因子(Recombinant Human Basic Fibroblast Growth Factor,rh-bFGF)与伤口护理软膏联合应用于慢性难愈性创面的疗效.方法:选取2021年9月-2024年9月于四川省骨科医院收治的104例慢性难愈性创面患者,按照不同治疗方法分为对照组(rh-bFGF治疗)52例和观察组(rh-bFGF联合伤口护理软膏治疗)52例.比较两组创面愈合时间、完全愈合患者占比、临床疗效、疼痛评分、瘢痕评分、C反应蛋白(CRP)、白细胞介素-6(IL-6)及白细胞计数(WBC)水平及不良反应发生情况.结果:治疗2周后,两组创面完全愈合率及总有效率比较差异无统计学意义(P＞0.05);观察组创面愈合时间短于对照组(P＜0.05).治疗2周后,观察组创面疼痛VAS评分低于对照组(P＜0.05);治疗3 d后,观察组IL-6、WBC及CRP水平均低于对照组(P＜0.05).治疗期间,两组不良反应发生率比较差异无统计学意义(P＞0.05).创面愈合后3个月,对照组VSS评分高于观察组(P＜0.05).结论:rh-bFGF联合伤口护理软膏治疗慢性难愈性创面可早期控制炎症、缩短创面愈合时间、缓解疼痛、抑制瘢痕形成,值得临床推荐.
Objective To explore the therapeutic effect of combining recombinant human basic fibroblast growth factor(rh-bFGF)with wound care ointment in the treatment of chronic refractory wounds.Methods The selection process involved 104 patients with chronic refractory wounds who were admitted to Sichuan Provincial Orthopedic Hospital between September 2021 and September 2024.These patients were randomly allocated into two groups:the control group(n=52),which received treatment with recombinant human basic fibroblast growth factor(rh-bFGF),and the observation group(n=52),which was treated with a combination of rh-bFGF and ointment wound dressing.Subsequently,multiple parameters were compared between the two groups.These parameters included wound healing time,the proportion of patients achieving complete wound healing,clinical effcacy,pain score,scar score,levels of interleukin-6(IL-6),C-reactive protein(CRP),white blood cell count(WBC),and the incidence of adverse events.Results After two weeks of treatment,there was no statistically significant difference in the complete healing rate and total effective rate of the wounds between the two groups(P＞0.05).The healing time of the wounds in the observation group was shorter than that in the control group(P＜0.05).Two weeks after treatment,the VAS score of pain in the observation group was lower than that in the control group(P＜0.05).3 days after treatment,the levels of IL-6,WBC and CRP in the observation group were all lower than those in the control group(P＜0.05).During the treatment period,there was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Three months after wound healing,the VSS score of the control group was higher than that of the observation group(P＜0.05).Conclusion The combination of rh-bFGF and wound care ointment for the treatment of chronic refractory wounds can effectively control inflammation at an early stage,shorten the wound healing time,relieve pain,and inhibit scar formation.It is worthy of clinical recommendation.
梁玉祥;郎志刚;张旭;何冬;李可烨
四川省骨科医院骨病科 四川 成都 610041四川省骨科医院骨病科 四川 成都 610041四川省骨科医院骨病科 四川 成都 610041四川省骨科医院骨病科 四川 成都 610041四川省骨科医院骨病科 四川 成都 610041
医药卫生
慢性难愈性创面重组人碱性成纤维细胞生长因子(rh-bFGF)伤口护理软膏临床疗效瘢痕
chronic refractory woundsrecombinant human basic fibroblast growth factor(rh-bFGF)ointment wound dressingclinical effectscar
《中国美容医学》 2026 (10)
4-8,5
2021年四川省医学会伤口疾病(泰阁)专项科研课题(编号:2021TG42)
评论